Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_assertion type Assertion NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_head.
- NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_assertion description "[MRP gene expression, determined by RNase protection assay and chemosensitivity to doxorubicin, etoposide and cisplatin, determined by MTT assay, were assessed in 18 non-drug-selected lung-cancer cell lines (10 small-cell lung cancer, 6 non-small-cell lung cancer, and 1 carcinoid).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_provenance.
- NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_assertion evidence source_evidence_literature NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_provenance.
- NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_assertion SIO_000772 8647646 NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_provenance.
- NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_assertion wasDerivedFrom befree-20140225 NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_provenance.
- NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_assertion wasGeneratedBy ECO_0000203 NP811641.RA1juO0GpCVfFc0ZRD2finlHFg_tLsZ4iH-miw6gS2WFI130_provenance.